RUA: FY25 revenue soared and losses narrowed, but further capital is needed to fuel global growth

About this update from Rua Bioscience Ltd.

Revenue surged nearly sixfold to $1.90m in FY25, with losses sharply reduced and strong sales momentum across five international markets. Additional capital is needed to sustain growth, with further expansion expected in FY26.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Rua Bioscience Ltd.